Blog

PHOENIX, AZ / ACCESS Newswire / November 18, 2025 / As discussions around body image, representation, and professional visibility intensify, Do It Fat arrives at a pivotal cultural moment. Brand strategist and CEO Sara Chambers tackles a striking disconnect many women experience: the belief that their worth is tied to their waistline and how these negative thoughts hold them back from stepping fully into their power.

The book delivers cultural critique, personal narrative, and actionable reflection, inviting readers to ask: Why have I measured my worth in pounds and inches? Already making waves, Do It Fat has reached #1 in Feminist Theory and Self-Help for Eating Disorders & Body Image Issues, and #2 in Social Sciences, cementing its relevance and resonance.

“Women are delaying major life opportunities, careers, public visibility, and events, because of how they feel about their body,” Chambers explains.

The fall off in opportunity is more than anecdotal: unexplored promotion, muted voices, and silenced ambition are all part of the cost of internalized body shame. Chambers argues that too many women delay career moves, silence ideas, or opt out of opportunities, not due to a lack of capability, but due to how they feel about their bodies. Chambers writes, “The real cost of body shame isn’t that it shrinks our bodies. It shrinks our lives.”

Bestselling book Do It Fat. Book cover and creative direction by Elly & Nora.

A 2024 study recently found that 37.7 percent of females reported significant body-image dissatisfaction, compared to 24 percent of males, and more than half of respondents with a higher body mass index reported elevated dissatisfaction.These findings highlight the ways weight and appearance shape women’s self-perception, ambition, and visibility.

With more than two decades of helping entrepreneurs clarify their message and own their space, Chambers is uniquely positioned to bridge branding and body politics. Liz Brinkman, founder of On the Brink Nutrition, describes the book as “a bold, unapologetic celebration of bodies that challenges the myths and stigma so many of us carry.”

Author Sara Chambers, beautifully photographed by Lisa Whalen.

At the core of Do It Fat lies a powerful idea: showing up in the body you have today is an act of rebellion. The book explores how diet culture, the male gaze, and beauty standards have become unseen barriers to leadership, forcing women to question not just how they look, but whether they are “allowed” to lead.

Do It Fat is more than a personal memoir or feel-good self-help book. As Dr. Lisa Nichole Folden notes, it “leans into the ‘both’ and the ‘and’ of body image, diet culture, and beauty standards … Sara’s work is raw, unfiltered, based on both lived experience and pertinent research.”

Readers also receive tools, including reflection prompts, exercises in visibility and self-trust, and guidance for decoupling ambition from body size. It offers a roadmap for women to reclaim their voice, take up space, and stop shrinking, literally and figuratively.

And the timing couldn’t be more urgent. Data shows that negative body image correlates with lowered self-esteem and self-efficacy, both of which are tightly linked to career and leadership outcomes.At the same time, social media and emerging narratives around weight-loss drugs and fix-it-bodies are contributing to a polarized cultural moment. Do It Fat intervenes in that discourse, offering instead a message of presence, agency, and autonomy: You don’t need to shrink to matter.

Do It Fat launches today, November 18, 2025, with first-week proceeds benefiting The Body Positive, a nonprofit dedicated to body trust and empowerment. In-person and virtual events accompany the launch, including a virtual book club discussion with the nonprofit’s leadership and an intimate evening celebration in Phoenix.

About the Author

Sara Chambers is the CEO of Elly & Nora Creative, a branding agency helping women entrepreneurs align purpose, visibility, and power. She is also the founder of Chicks Who Give a Hoot, a nonprofit mobilising women as a force for good through media and mentorship. Do It Fat is her debut book.

Do It Fat is available beginning November 18, 2025.

For more information, visit DoItFatBook.com

For further information, please contact: dottie@rebeccacafiero.com.

SOURCE: Elly & Nora Creative

View the original press release on ACCESS Newswire

NEW YORK, NY / ACCESS Newswire / November 18, 2025 / There are moments in history when emerging threats move faster than the systems built to defend against them. Today, we are in one of those moments. As global supply chains grow more complex and interconnected, new forms of infiltration are quietly taking shape inside the very infrastructure that powers modern life. These risks are not theoretical. They are structural, and they are accelerating.

Recent concerns about compromised devices and unverified components reflect a broader challenge facing every modern nation: critical infrastructure often depends on materials and technologies that pass through lengthy, opaque supply chains before reaching the people who rely on them. In an environment this interconnected, even a single blind spot can become an entry point. That is the issue the world must understand clearly and calmly.

For years, SMX (NASDAQ:SMX) has worked at the molecular level to help provide that clarity. By embedding identity and traceability directly into materials at the point of origin, SMX enables end-to-end verification that follows a product throughout its entire lifecycle. This ability to authenticate materials is not a concept and not a future aspiration. It is an operational system currently used across industries such as natural rubber, precious metals, recycling, advanced manufacturing, and hardware supply chains.

These capabilities exist. They are proven. And they are available to any sector that needs them.

A Global Challenge Without a Villain

Don’t underestimate the SMX touch points. Every sector can benefit. The vulnerabilities in supply chains and critical infrastructure are not tied to any one actor, nation, or group. In a globalized economy, infiltration can originate from anywhere and travel through any unverified device, material, or component. A system without transparency creates unintentional opportunities for misuse.

The objective is not to blame or accuse. It is to strengthen resilience.

Complex supply chains, from consumer products to industrial materials to advanced electronics, now sit at the heart of national stability. Safeguarding these systems requires traceability that starts at the source and verification that is foundational, not superficial.

Why This Matters Now

The consequences of a compromised infrastructure reach far beyond inconvenience. Modern society depends on electricity, water systems, transportation networks, logistics, communication platforms, and digital coordination. If any part of this network is disrupted at scale, the effects can cascade rapidly.

If the grid goes down, essential systems become vulnerable. Gas distribution stops. Water treatment facilities stall. Grocery shelves can empty within days. Hospitals face critical shortages. Truckers struggle to move feedstock. Refrigeration fails. Electric vehicles cannot charge. Before long, millions confront conditions that strain every aspect of modern life.

These scenarios are not predictions of doom. They are practical examples of why supply chain integrity is essential to national resilience.

Awareness, Understanding, and the Role of New Tools

This is why understanding emerging tools matters. SMX’s molecular identity system is already supporting partners across several industries, providing transparent material verification from the outset of the supply chain. It’s proving a vital resource for strengthening resilience wherever it is needed.

That’s because molecular-level verification does more than improve transparency. It ensures that materials have memory, that supply chains have accountability, and that infrastructure has the foundational protection required for a connected world. These are not theoretical benefits. They are measurable, operational, and available today.

The risks facing modern infrastructure are real, but so are the technologies capable of mitigating them. This moment calls for clarity, cooperation, and thoughtful engagement across both public and private sectors. Strengthening supply chains is no longer an abstract discussion. It is a practical, achievable step toward safeguarding essential systems.

The Path Forward

The path ahead requires more than awareness. It requires decisive steps to strengthen the systems on which modern life depends. Supply chain transparency is no longer a technical preference. It is an essential component of national resilience.

Infiltration may be a quiet threat, but the solutions are tangible and ready for deployment. Technologies that provide material identity and verification at the source give industries and institutions the tools to reduce risk, reinforce infrastructure, and prepare for an increasingly complex global environment. These are practical measures that can be put to work today, not distant concepts waiting for future progress.

SMX has built technology designed for this moment, technology that proves resilience is achievable when verification becomes foundational. As the world grows more interconnected, the need to secure what we depend on will only intensify. Strengthening supply chains is not a matter of caution. It is a matter of responsibility.

The time to act is now.

About SMX

As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

Forward-Looking Statements

This editorial contains forward-looking statements within the meaning of U.S. federal securities laws, including the Private Securities Litigation Reform Act of 1995. These statements reflect discussions concerning global security conditions, supply chain vulnerabilities, international regulatory environments, and the potential capabilities and future adoption of SMX technologies. Forward-looking statements are not historical facts. They are based on current expectations, beliefs, estimates and projections about future events that remain uncertain and that may differ materially from actual outcomes.

Words such as “expect,” “believe,” “anticipate,” “intend,” “estimate,” “could,” “should,” “may,” “will,” “project,” “potential,” “future,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements include these identifying terms. Such statements include, but are not limited to, expectations regarding global threats to infrastructure, the evolution of international supply chain standards, regulatory adoption of material-level verification technologies, and the potential for SMX’s molecular identity platform to address national security, sustainability, traceability, and circular-economy challenges.

These statements involve risks, uncertainties, and factors outside SMX’s control, including geopolitical developments, legislative decisions, market adoption rates, technological advancements, enforcement practices, shifts in global trade policy, and third-party reliance on unverifiable data systems. Actual results and developments may differ significantly from those expressed or implied in these forward-looking statements. Readers are encouraged to review the risk factors and disclosures contained in SMX’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K.

Forward-looking statements in this editorial are made only as of the date of publication. SMX undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events, changes in circumstances, or new information, except as required by applicable law.

CONTACT:

EMAIL: info@securitymattersltd.com

SOURCE: SMX (Security Matters) Public Limited

View the original press release on ACCESS Newswire

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / November 19, 2025 / CoTec Holdings Corp. (TSXV:CTH)(OTCQB:CTHCF) (“CoTec” or the “Company”) is pleased to announce that it has filed its unaudited interim condensed consolidated financial statements and the accompanying management’s discussion and analysis (“MD&A”) for the three and nine months ended September 30, 2025. The financial statements and MD&A can be accessed under the Company’s SEDAR+ profile at www.sedarplus.ca.

Julian Treger, CoTec CEO commented: “During the third quarter we delivered significant progress across our portfolio, accelerated our strategic initiatives, advanced our flagship projects toward key milestones and completed a very successful oversubscribed financing initiative. At our U.S.‐based rare earth magnet recycling joint venture, HyProMag USA LLC (“HyProMag USA”), the detailed design and engineering phase remains on schedule and within budget, site selection and lease negotiations are in final stages. ILS has been engaged as our first feedstock supplier and we are working on accelerating the expansion from one recycling and magnet manufacturing hub in Fort Worth, Texas to three hubs over the next three to five years.

Our Québec iron tailings project at Lac Jeannine is moving into feasibility study following the successful completion of our 2025 infill and expansion drilling program, with drilling results expected in Q1, 2026. The feasibility study will include the application of Salter gravity separation technology, which we believe could add significant value to the project.

The Company continues to explore other opportunities in iron ore, copper and other minerals that could benefit from our suite of technologies. We believe the Company’s market price remain materially undervalued compared to the intrinsic value of our asset base and technology portfolio and we have significantly stepped up our marketing efforts to reduce this gap.”

The Company reported a net loss of approximately $2.9 million for the quarter and $8.1 million year-to-date. However, administrative overheads, comprising Professional consulting fees and General and administrative expenses totaled only $1.13m and $2.97m for the quarter and the year to date respectively, with the remainder of the loss mainly derived from non-cash items, accounting adjustments and finance expense provisions.

Highlights for the quarter include:

Operational – HyProMag USA

• Detailed Design and Engineering (“DDE”) more than 25% complete, on time and within budget

• Expanded Texas hub scope from two to three HPMS vessels, increasing NdFeB co-product output

• Commissioned expansion studies evaluating additional hubs in South Carolina and Nevada, which would expand HyProMag USA from one integrated hub to a three-hub national platform – effectively tripling the scale of the original business contemplated in the Feasibility Study

• Commissioned Worley to contemplate a concept study on “Long Loop” recycling

• Executed a feedstock supply and pre-processing site-sharing agreement with Intelligent Lifecycle Solutions (“ILS”) covering South Carolina and Nevada; stockpiling of e-waste has commenced

• Purchased three Inserma/PCB pre-processing units for Texas, Nevada, and South Carolina, with delivery expected before year-end

• Continued engagement with U.S. federal and state agencies and commercial lenders regarding project financing and incentives

Operational – Lac Jeannine

• Completed the 2025 infill and expansion drill program on August 27, 2025; assays expected in Q1 2026

• Purchased a commercial-scale multi-gravity separation unit from Salter to evaluate ultra-fine iron recovery

• Ongoing engagement with the Government of Québec, local stakeholders, and First Nations

Corporate

• Completed the $13.5 million Listed Issuer Financing Exemption (“LIFE”) and concurrent private placement financing, 35% oversubscribed

• Secured $6.6 million in new convertible loan facilities from Kings Chapel and Epic Capital; no amounts drawn as at quarter-end

• Converted $6.851 million of prior Kings Chapel convertible loans into equity following the automatic conversion trigger

• Ended the quarter with $5.8 million in cash and cash equivalents, strengthened by the Q3 financing activities

• Reported a net loss of $2.9 million for the quarter, driven primarily by G&A expenses, non-cash foreign-exchange and valuation adjustments, and share-based compensation

About CoTec

CoTec is a publicly traded investment issuer listed on the TSX Venture Exchange (“TSX-V”) and the OTCQB and trades under the symbols CTH and CTHCF respectively. CoTec Holdings Corp. is a forward-thinking resource extraction company committed to revolutionizing the global metals and minerals industry through innovative, environmentally sustainable technologies and strategic asset acquisitions. With a mission to drive the sector toward a low-carbon future, CoTec employs a dual approach: investing in disruptive mineral extraction technologies that enhance efficiency and sustainability while applying these technologies to undervalued mining assets to unlock their full potential. By focusing on recycling, waste mining, and scalable solutions, the Company accelerates the production of critical minerals, shortens development timelines, and reduces environmental impact. CoTec’s strategic model delivers low capital requirements, rapid revenue generation, and high barriers to entry, positioning it as a leading mid-tier disruptor in the commodities sector.

Please visit www.cotec.ca.

For further information, please contact:

Braam Jonker – (604) 992-5600

Forward-Looking Information Cautionary Statement

Statements in this press release regarding the Company and its investments which are not historical facts are “forward-looking statements” which involve risks and uncertainties, including statements relating to the roll out of its HyProMag USA and Lac Jeannine projects and its investments in MagIron, Ceibo, BSL and Salter, as well as management’s expectations with respect to other current and potential future investments and the benefits to the Company which may be implied from such statements. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements, due to known and unknown risks and uncertainties affecting the Company, including but not limited to resource and reserve risks; environmental risks and costs; labor costs and shortages; uncertain supply and price fluctuations in materials; increases in energy costs; labor disputes and work stoppages; leasing costs and the availability of equipment; heavy equipment demand and availability; contractor and subcontractor performance issues; worksite safety issues; project delays and cost overruns; extreme weather conditions; and social disruptions. For further details regarding risks and uncertainties facing the Company please refer to “Risk Factors” in the Company’s filing statement dated April 6, 2022, a copy of which may be found under the Company’s SEDAR+ profile at www.sedarplus.ca. The Company assumes no responsibility to update forward-looking statements in this press release except as required by law. Readers should not place undue reliance on the forward-looking statements and information contained in this news release and are encouraged to read the Company’s continuous disclosure documents which are available on SEDAR+ at www.sedarplus.ca.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

SOURCE: CoTec Holdings Corp.

View the original press release on ACCESS Newswire

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer.

TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology.

Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization ¹ . At present, there are no FDA approved ADC therapies for cholangiocarcinoma.

To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to experimental therapies that have the potential to treat these diseases. In the United States, a rare disease is defined as any condition that affects fewer than 200,000 patients. After granting Orphan Drug Designation, the US FDA qualifies companies or drug developers incentives such as tax credits for clinical trials, exemption from user fees, and marketing exclusivity².

In August 2025, OBI launched a phase I/II clinical trial in the United States and Taiwan, recruiting patients with advanced solid tumors. The objectives of the trial are to study the safety, pharmacokinetics, and preliminary efficacy profile of OBI-902 in these patient populations.

Heidi Wang, Ph.D, OBI Pharma’s Chief Executive Officer noted, “Based on our preclinical data, OBI-902 has several important advantages over other TROP2 ADCs either approved or in development; including high stability in blood circulation, excellent bystander effect that extends the killing to neighboring cancer cells lacking TROP2 expression, potential ability to overcome drug resistance, and outstanding activity in animal and organoid models of cancer. Importantly, this marks the first time an ADC that incorporates OBI’s proprietary GlycOBI^® ADC technology is being evaluated in patients, including those diagnosed with cholangiocarcinoma. We look forward to investigating this potential best-in-class TROP2 ADC in the clinic.”

About OBI-902

OBI-902 is a TROP2-targeted antibody-drug conjugate (ADC) that carries a potent topoisomerase I inhibitor payload to kill tumor cells and with a drug-antibody ratio (DAR) of 4. TROP2 is highly expressed in a variety of solid tumors such as breast, lung, biliary, bile duct (cholangiocarcinoma), ovarian, gastric, and many other cancer types, rendering it an ideal target for cancer therapy.

OBI-902 is a novel site-specific glycan-conjugated ADC using OBI’s proprietary GlycOBI platform, which provides improved stability and enhanced hydrophilicity. OBI-902 demonstrated remarkable antitumor efficacy, improved pharmacokinetic characteristics, and a favorable safety profile in various animal models. The IND of OBI-902 was cleared by the US FDA on April 30, 2025.

Since December 2021, OBI has been granted by Biosion, Inc. (www.biosion.com) an exclusive, worldwide (except in China) license to a TROP2 targeting antibody amino acid sequence. Biosion holds exclusive rights to that antibody sequence in China. OBI holds worldwide commercial rights to OBI-902, except for the rights pertaining to the antibody in China.

About GlycOBI^®

OBI has developed a unique clinical stage, glycan-based site-specific ADC technology (GlycOBI^®), which is in a ‘Plug and Play’ format and compatible with any antibodies, linkers, and payloads in drug-antibody ratio (DAR) up to 16. Utilizing OBI’s proprietary dual-function enzyme (EndoSymeOBI^®) and linker technology (HYPrOBI^®), homogenous ADCs are manufactured with an efficient and scalable process under GMP conditions. The conjugation process of GlycOBI^® avoids disrupting the antibody structure and ensures the ADC has similar biophysical characteristics to the native antibody. Furthermore, OBI’s linker technology has improved conjugation efficiency of the payload, reduced aggregation propensity, which provides advantages on manufacturing ADC products. GlycOBI^® conjugated ADCs have overcome the limitations of traditional ADCs and achieved better antitumor activity and stability in various in vivo animal studies. GlycOBI^®, EndoSymeOBI^®, and HYPrOBI^® are part of the armamentarium of OBI’s Obrion™ ADC Enabling Technologies that also include ThiOBI^® and GlycOBI DUO™. OBI-902 is the first ADC utilizing OBI’s Obrion™ ADC enabling technology for evaluation of safety and efficacy in Cancer, currently under Phase I/II clinical trial in the US and Taiwan.

About OBI Pharma

OBI is a clinical stage global oncology company that is headquartered in Taiwan and established in 2002. Its mission, together with its wholly owned subsidiary OBI Pharma USA, Inc., is to develop novel therapeutic agents for patients with high unmet medical needs.

OBI’s primary focus is the development of novel ADCs, including the first-generation cysteine-based TROP2 ADC, OBI-992. Using the company’s proprietary ADC enabling technology, GlycOBI^®, powered by EndoSymeOBI^® and HYPrOBI^®; OBI has created its next-generation novel ADC pipeline, including monospecific: OBI-902 (TROP2), OBI-904 (Nectin-4), bispecific single payload (HER2 x TROP2), and bispecific, dual payload (cMET x HER3) ADCs. To broaden the applicability of linker technology, HYPrOBI^®, OBI further developed a novel ThiOBI^® platform to enable irreversible cysteine-based conjugation. Additionally, OBI’s pipeline includes the first-in-class AKR1C3-targeted small-molecule prodrug OBI-3424, which selectively releases a potent DNA-alkylating antitumor agent in the presence of the aldo-keto reductase 1C3 (AKR1C3) enzyme that is highly expressed in tumors. Additional information can be found at www.obipharma.com.

GlycOBI^®, EndoSymeOBI^®, ThiOBI^® and HYPrOBI^®are registered trademarks of OBI Pharma. Obrion™ and GlycOBI DUO™ are trademarks under registration.

¹National Institute of Health for Rare Diseases. Sept. 2025

https://rarediseases.info.nih.gov/diseases/9304/cholangiocarcinoma

²US FDA website. Designating an Orphan Product: Drugs and Biological Products Sept.25 https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products

Forward-Looking Statements

Statements included in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about future clinical trials, results and the timing of such trials and results. Such risk factors are identified and discussed from time to time in OBI Pharma’s reports and presentations, including OBI Pharma’s filings with the Taiwan Securities and Futures Bureau.

COMPANY CONTACT:
Kevin Poulos, Chief Business Officer
OBI Pharma USA, Inc.
+1 (619) 537 7698, ext. 102
kpoulos@obipharma.com

SOURCE: OBI Pharma USA, Inc.

View the original press release on ACCESS Newswire

REGINA, SK / ACCESS Newswire / November 18, 2025 / B&Bowa’s Cleaning Services, one of Saskatchewan’s top-rated and most trusted cleaning companies, has won the 2025 Consumer Choice Award in the Residential & Commercial Cleaning Services category for Regina. This recognition honours B&Bowa’s dedication to transforming homes, businesses, and industrial facilities into spotless, healthy environments with care, consistency, and exceptional service.

Founded in 2016 by a dedicated husband-and-wife team, B&Bowa’s Cleaning has grown from a small home-based operation into a full-scale company trusted by families and businesses across Regina and surrounding areas.

A Local Success Story Built on Clean Results

What started as a passion for spotless homes and happy clients has become a thriving cleaning company that now maintains over 150 homes and millions of square feet of commercial space every month. Today, B&Bowa’s Cleaning is powered by a team of 45 full-time and 20 part-time professional cleaners who share the same commitment to delivering quality and peace of mind.

“Winning the Consumer Choice Award is an incredible honour for our entire team and a reflection of the trust our clients place in us every day,” said the B&Bowa’s Cleaning Services team. “Our mission is simple: deliver exceptional results every time, so our clients can focus on what matters most.”

Complete Cleaning Solutions for Every Space

B&Bowa’s Cleaning offers a wide range of services to meet the unique needs of residential, commercial, and industrial clients. Their trusted services include:

• Commercial Cleaning: Regular janitorial services, nightly office cleaning, and common area maintenance.

• Residential Cleaning: One-time deep cleans, scheduled home cleaning, move-in/move-out services, and custom house care.

• Industrial Cleaning: Heavy-duty facility cleaning, floor maintenance for warehouses and production sites.

• Post-Construction Cleanup: Detailed cleaning to remove dust and debris after renovations or new builds.

• Disinfection and Sanitation: Thorough sanitizing solutions to maintain healthy spaces in homes and workplaces.

• Window Cleaning: Interior and exterior window washing for homes and businesses.

• Power Washing: High-pressure cleaning for exteriors, driveways, and building facades.

• Garage and Parking Lot Cleaning: Clearing debris and maintaining clean, safe parking areas.

• Carpet and Upholstery Cleaning: Deep cleaning services to refresh carpets, rugs, and furniture.

Every service is delivered by trained professionals using high-quality products, advanced equipment, and proven methods to ensure top-tier results.

A Dedicated Team You Can Trust

At the heart of B&Bowa’s success is a dedicated, background-checked team that takes pride in making every space shine. Team members receive extensive training, follow detailed quality checklists, and undergo regular performance reviews to keep standards high.

Clients appreciate the company’s open communication, consistent scheduling, and genuine respect for their homes and workplaces.

Rooted in the Regina Community

As a locally owned and operated company, B&Bowa’s Cleaning is deeply invested in the community it serves. The company creates good local jobs, supports local families, and values long-term relationships built on trust, transparency, and quality service.

Word-of-mouth referrals and loyal clients have been key to B&Bowa’s steady growth and its reputation as a reliable partner for clean, healthy spaces.

Raising the Bar for Clean, Year After Year

With this Consumer Choice Award win, B&Bowa’s Cleaning Services plans to keep growing its skilled team, expand eco-friendly cleaning options, and invest in technology to make scheduling and communication even smoother for busy clients.

One thing will never change: the founders’ promise to deliver spotless results, every time, so clients can focus on what truly matters – not the mess.

To learn more about B&Bowa’s Cleaning Services or to get a personalized quote for your home, business, or facility, CLICK HERE or visit www.bbowascleaning.com.

About Consumer Choice Award
Consumer Choice Award has been recognizing and promoting business excellence in North America since 1987. Its rigorous selection process ensures that only the most outstanding service providers in each category win this prestigious recognition. Visit www.ccaward.com to learn more.

Contact Information
Sumi Saleh
Communications Manager
ssaleh@ccaward.com

SOURCE: Consumer Choice Award

View the original press release on ACCESS Newswire

Strengthened Balance Sheet and Continued Record Growth

TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / November 18, 2025 / Organto Foods Inc. (TSX-V:OGO)(OTCQX:OGOFF)(FSE:OGF0) (“Organto” or “the Company”), is pleased to announce its financial results for the three and nine-month periods ended September 30, 2025. All amounts are expressed in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), except where specifically noted.

Hi-Lites

Quarter Ended September 30, 2025

• Third quarter sales of $15.1 million, an increase of 189% versus the prior year. Largest third quarter sales in the history of the Company.

• Gross profit of $1.2 million, an increase of 101% versus the prior year. Largest third quarter gross profit dollars in the history of the Company.

• Cash operating expenses of 8.7% of sales versus 18.2% in the prior year. Cash operating costs as percentage of sales improved as business scales and overheads are leveraged.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $(0.7) million, reflecting improved operating results offset by the impact of losses on derivatives used to manage currency risk.

Nine-Month Period Ended June 30, 2025

• Sales of $45.9 million, an increase of 222% versus the prior year, and already 122% greater than fiscal 2024 total sales of $20.7 million.

• Gross profit of $3.6 million, an increase of 208% versus the first nine months of the prior year, and already 100% greater than fiscal 2024 total gross profit of $1.8 million.

• Cash operating expenses of 7.3% of sales versus 13.4% in the prior year. Cash operating costs as percentage of sales demonstrate continued improvement as the business scales and overheads are leveraged.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $(0.9) million, reflecting improved operating results offset by the impact of losses on derivatives used to manage currency risk.

• Balance sheet significantly strengthened as a result of improved operations, debt restructuring and financing activities:

• Cash of $8.8 million (excluding restricted cash) versus $0.3 million at December 31, 2024.

• Working capital of $8.6 million versus negative working capital of $14.6 million at December 31, 2024.

• Short-term loans and convertible debentures reduced to $2.5 million versus $12.5 million at December 31, 2024.

“We believe our results for the third quarter are a solid reflection of the strong momentum and financial strength we are building in our business. These results are the outcome of the extensive restructuring and business realignment we’ve executed over the past 21 months, which we believe sets a solid foundation for sustained growth, stability, and a clear path to profitability. The combination of our growing business, which continues to deliver, and our strengthened financial position, leads to our optimism as we continue to build a world-class company serving growing healthy foods markets and in doing so creating lasting value for our partners, customers, team members and shareholders”, commented Steve Bromley, Co-Chair and Chief Executive Officer.

Fiscal 2025 Third Quarter Results Overview

• Sales of $15.1 million versus $5.2 million in the prior year, an increase of approximately 189%. Sales grew as new customers were added, while a number of existing customers increased their purchases. Q-3 sales represent the largest third quarter sales in the history of the Company and 73% of total fiscal 2024 sales of $20.7 million.

• Gross profit of $1.2 million or 8.2% of sales, versus $0.6 million or 11.8% of sales in the prior year, an increase of approximately 101% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $0.7 million or 4.5% of sales when accounting for the impact of realized currency hedging activities, versus $0.6 million or 11.8% of sales in the prior year when there was no impact from hedging activities.

• Cash operating expenses of $1.3 million or 8.7% of sales versus $0.9 million or 18.2% of sales in the prior year. Operating expenses have stabilized following the sale of three subsidiaries in Q-2 2024, and reflect incremental costs to support the growth of our business and costs related to our rebranding initiatives.

• Loss from operations of $0.4 million versus a loss of $0.5 million in the prior year.

• Net loss for the period of $2.0 million after accounting for interest and accretion costs of $0.1 million and net losses on derivatives totaling $0.4 million. Net loss also includes a number of non-recurring costs including debt restructuring costs of $0.1 million and losses on the settlement of debt of $1.7 million. Adjusted for non-recurring costs, adjusted net income was $0.2 million versus a net loss in the prior year of $0.8 million.

Fiscal 2025 Nine-Month Results Overview

• Sales of $45.9 million versus $14.3 million in the prior year, an increase of approximately 222%. Sales have grown as new customers were added, and a number of existing customers increased their purchases. Nine-month sales represent an increase of 122% over total fiscal 2024 sales of $20.7 million.

• Gross profit of $3.6 million or 7.7% of sales, versus $1.2 million or 8.2% of sales in the prior year, an increase of approximately 208% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $2.5 million or 5.5% of sales when accounting for the impact of realized currency hedging activities, versus $1.1 million or 7.6% of sales in the prior year.

• Cash operating expenses of $3.4 million or 7.3% of sales versus $1.9 million or 13.4% of sales in the prior year. Operating expenses have stabilized following the sale of three subsidiaries in Q-2 2024, though have increased due to the assumption of operating expenses that were previously borne by the subsidiaries sold, as well as incremental costs to support the growth of our business.

• Loss from operations of $0.6 million versus a loss of $1.1 million in the prior year.

• Net loss for the period of $9.6 million after accounting for interest and accretion costs of $0.6 million and net losses on derivatives of $2.3 million. Net loss also includes a number of non-recurring costs including debt restructuring costs of $0.8 million and losses on the settlement of debt of $5.5 million. Net loss in the prior year was $0.3 million, driven by a gain from the dissolution of one of our subsidiaries of $0.4 million and income related to the sale of three operating subsidiaries of $1.2 million, offset by losses related to continuing operations.

The Company’s Financial Statements and Management Discussion and Analysis for the three and nine-month periods ended September 30, 2025., as well as its Audited Financial Statements and accompanying Management’s Discussion and Analysis for the year ended December 31, 2024 are available at www.SEDARplus.ca or at the Company’s website at www.organto.com under the Investors tab.

Exercise of Warrants

In June 2025 the Company closed a private placement and issued 4,000,000 units at a price of $0.25 per unit for proceeds of $1,000,000. Each unit consisted of one common share and one half of a share purchase warrant. Each whole warrant entitles the holder to purchase one common share at a price of $0.35 until December 2026. The holder of 2,000,000 half a share purchase warrants has exercised their right to purchase 1,000,000 million common shares at a price of $0.35 per share. The Company received proceeds of $350,000, and as a result, issued 1,000,000 common shares. The common shares were subject to a hold period that expired on October 27, 2025.

ON BEHALF OF THE BOARD,

Steve Bromley
Co-Chair and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For more information contact:
info@organto.com
John Rathwell, Senior Vice President, Corporate Development
647 629 0018

(1) The information presented herein refers to the non-IFRS financial measures of adjusted gross profit and EBITDA. We hedge currencies for certain product categories where either the supply or sales commitments are fixed in foreign currencies. The gains and losses from these hedging activities are combined with gross profit to determine adjusted gross profit. We also refer to EBITDA, which is Earnings before interest, taxes, depreciation and amortization. These two measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS. Non-IFRS financial measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS and are unlikely to be comparable to similar measures presented by other issuers. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures. The Company believes that securities analysts, investors and other interested parties frequently use non-IFRS financial measures in the evaluation of the Company. The Company’s management also uses non-IFRS financial measures to facilitate operating performance comparisons from period to period and to prepare annual operating budgets and forecasts.

ABOUT ORGANTO FOODS

Organto is an integrated provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-light business model to serve a growing socially responsible and health-conscious consumer around the globe. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that the impact of these restructuring efforts is a key driver of its third quarter and nine-month results; Organto’s belief that the combination of its growing business, combined with its strengthened financial position, leads to optimism for the future; Organto’s belief that it remains focused on building a world class company focused on growing healthy foods markets with the goal of building lasting shareholder value; management’s beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

LOXLEY, AL / ACCESS Newswire / November 18, 2025 / Kaishan USA, a leading manufacturer of industrial air compressors, announced today it will serve as a major sponsor of the 2025 IS4S Salute to Veterans Bowl. The event takes place on December 16, 2025, at the Cramton Bowl in Montgomery, Alabama. The nationally televised matchup, featuring a team from the Mid-American Conference (MAC) against a team from the Sun Belt Conference, will air live on ESPN.

The Salute to Veterans Bowl, formerly known as the Camellia Bowl, stands as one of the nation’s most significant celebrations of military service. The event highlights game-day honors, family tributes and community initiatives that recognize the bravery and dedication of America’s service members and veterans.

Kaishan’s sponsorship reflects the company’s deep, longstanding respect for the military community. Through partnerships with veteran-focused organizations, such as the Gary Sinise Foundation, the company has actively engaged in service-related initiatives and employed former service members across its U.S. operations, building a culture defined by appreciation, humility and gratitude.

Clay Norrell, executive director at ESPN Events, emphasized the importance of this partnership. “The Salute to Veterans Bowl pays tribute to the courage, commitment and resilience of America’s service members. Kaishan USA consistently demonstrates these values. Their support advances our mission and enriches the event for every veteran and family we recognize. We’re proud to welcome Kaishan USA as a major sponsor for 2025.”

Bubba Phillips, marketing manager at Kaishan USA, reinforced the significance of this collaboration. “Supporting our military and their families isn’t just a gesture-it’s who we are. The Salute to Veterans Bowl allows us to express our gratitude to this extraordinary community in a meaningful way. We’re honored to be part of this event.”

About Kaishan USA

Kaishan USA is a leading manufacturer of industrial air compressors designed, built and supported in Loxley, Alabama. With a nationwide distribution network and a dedication to American craftsmanship, Kaishan delivers dependable compressed air solutions to manufacturers and critical industries across the country. The company actively supports veteran organizations and initiatives that empower families, communities and opportunities for those who serve.

About the IS4S Salute to Veterans Bowl

The IS4S Salute to Veterans Bowl is an annual college football event honoring America’s active-duty military, veterans and their families. More than just a game, it has become a prominent tradition that showcases the military community’s service and sacrifice. Held at the historic Cramton Bowl in Montgomery, Alabama, and broadcast on ESPN, the event features teams from the Mid-American and Sun Belt Conferences.

SOURCE: Kaishan Compressor USA

View the original press release on ACCESS Newswire

• Strategic partnership between XCF Global and BGN to jointly develop global distribution and logistics infrastructure for SAF and other renewable fuels

• Seeks to expand XCF’s international reach into key markets including Europe and the Middle East through production, offtake, and co-branded distribution agreements

• Advances global renewable fuel supply chains to meet rapidly rising demand for SAF

HOUSTON, TEXAS / ACCESS Newswire / November 17, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a leader in advancing the decarbonization of the aviation industry through Sustainable Aviation Fuel (“SAF”), today announced that it has entered into a Memorandum of Understanding(“MOU”) with BGN INT US LLC (“BGN”), a global renewable fuels trading, marketing, and distribution company, to explore developing a global distribution and logistics partnership for SAF, renewable diesel (“RD”), and renewable naphtha (“RN”) (together, “renewable fuel”).

Under the MOU, XCF and BGN intend to evaluate opportunities to collaborate on renewable fuel production, marketing, and distribution across multiple regions around the world, including Europe and the Middle East. The proposed framework includes offtake and co-branded distribution agreements, as well as joint development of renewable fuel production capacity. In addition, the proposed strategic partnership seeks to promote the use of XCF’s SAF within industry trade associations and OEM networks, and throughout the customer value chain.

Chris Cooper, Chief Executive Officer of XCF Global, commented:

“This collaboration represents a critical step in expanding the global reach of renewable fuels. Partnering with BGN would enable us to extend our footprint, streamline logistics, and accelerate commercialization on a global scale with a world-class partner, as we prepare to meet surging demand for sustainable aviation fuel.

“This MOU reflects a shared vision to advance a scalable, commercially viable framework for global renewable fuel production and distribution.”

Cenan Ozmeral, President of BGN Int. US, LLC added:

“We are pleased to be partnering with US based XCF in this exciting venture. BGN and XCF share a common goal to expand access to renewable fuels and accelerate the decarbonization of the aviation industry. Together, we aim to combine XCF’s scalable production model with BGN’s marketing and distribution network to create a seamless, efficient supply chain from feedstock to finished fuel.

“BGN’s trading strength, risk management expertise, and integrated logistics network, will make SAF adoption practical and commercially viable for airlines seeking to meet tightening decarbonization targets. This is a major step, which we believe will have a significant impact on the aviation industry’s ability to reduce emissions, in one of the hardest-to-abate transport sectors.”

The collaboration underscores both companies’ commitment to building a robust global supply chain at a time when demand for SAF is expanding rapidly. According to the International Air Transport Association (IATA), airlines will need approximately 165 billion gallons of SAF annually by 2050 to meet net-zero emission targets. Meeting this demand would require the construction of up to 7,000 new facilities worldwide. Analysts project that the global SAF market could exceed $25 billion by 2030 and reach ~$270 billion by 2050, underscoring one of the most compelling growth opportunities in the global energy transition.

This MOU is non-binding, and execution remains subject to customary due diligence, technical validation, and final agreements.

About XCF Global, Inc.

XCF Global, Inc. is a pioneering sustainable aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. We develop and operate state-of-the-art SAF production facilities engineered to the highest levels of compliance, reliability, and quality, and are building partnerships across the energy and transportation sectors to scale SAF globally. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~159.2 million; <20% free float (as of November 17, 2025).

To learn more, visit www.xcf.global.

About BGN INT and BGN group of companies

BGN is an independent global energy and commodities group, and a market leader in transition fuels. With over 8 decades experience in the energy sector, we trade, distribute, store and finance energy solutions globally, handling approximately 50 million metric tons of commodities annually. BGN is present throughout the energy value chain, having established strong partnerships with refineries, producers, state oil companies and leading industrial and petro-chemical companies.

Our diversified and agile model provides reliable and affordable energy to meet today’s global demands, while driving industry-wide decarbonization. We are purposefully expanding into sustainable solutions including renewables, sustainable aviation fuel (SAF), LNG, ammonia, and critical minerals and metals, essential for the energy transition. Operating from our regional trading hubs in Geneva, Dubai, Singapore and Houston, we serve as a trusted partner to customers in over 120 countries. BGN is leading the energy transition by combining innovation, sustainability and partnership-led growth, to responsibly shape the future energy landscape.

To learn more, visit: https://bgn-int.com/.

Contacts

XCF Global:
C/O Camarco
XCFGlobal@camarco.co.uk

Media:
Camarco
Andrew Archer | Rosie Driscoll | Violet Wilson
XCFGlobal@camarco.co.uk

Forward-Looking Statements

This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses, including manufacturing and operating expenses and interest expenses, as a result of potential inflationary pressures, changes in interest rates and other factors; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to regain compliance with Nasdaq’s continued listing standards and thereafter continue to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing to fund its operations and business plan and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) the New Rise Reno production facility’s ability to produce renewable diesel in commercial quantities without interruption during the ongoing SAF ramp-up process; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (11) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (12) payment of fees, expenses and other costs related to the completion of the Business Combination and the New Rise acquisitions; (13) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (14) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (15) changes in applicable laws or regulations; (16) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (17) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (18) the availability of tax credits and other federal, state or local government support; (19) risks relating to XCF Global’s and New Rise’s key intellectual property rights, including the possible infringement of their intellectual property rights by third parties; (20) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (21) the effects of increased costs associated with operating as a public company; and (22) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global made or will make with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

SOURCE: XCF Global, Inc.

View the original press release on ACCESS Newswire

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925112608/nnvc-20250930x10q.htm).

Clinical Stage NV-387, a Single Drug, Meets Many Unmet Medical Needs in Viral Diseases
NV-387, based on a novel mechanism of action, and a novel nanomedicine technology that defines a new class of drugs, is a first-in-class broad-spectrum antiviral drug.

Viruses cannot escape NV-387 because no matter how much a virus changes, it continues to bind to the sulfated proteoglycan attachment receptor(s) of the host which the virus needs to cause infection as well as for human-to-human transmission. NV-387 mimics the critical features of the conserved attachment receptors on the host-side that over 90% of viruses are known to use.

This escape-resistant drug feature of NV-387 solves the biggest problem in antiviral medical countermeasures: Viruses readily evolve to escape the countermeasures in the field, whether vaccines, antibodies, or traditional small chemical drugs.

At present:

• There is no approved drug for Influenza that can be reliably predicted to be not escaped by the next potential epidemic or pandemic Influenza virus, including H5N1. All approved influenza drugs are known to be readily escaped by Influenza variants.

• Additionally, in the current season, the mutated clade K of the A/H3N2 subtype is dominant in the Northern hemisphere, and the seasonal Influenza vaccine is “mismatched” (i.e. it contains the older variant, clade J, of A/H3N2). When the vaccine is mismatched, the overall vaccine efficacy as determined post-season has been as low as 11-17% ^[1] .

• There is no approved drug for RSV, although three different antibodies have been approved for pre-exposure protection of infants from potential risk of RSV infection, and some vaccines have been approved for use in geriatric patients and adults at risk, as well as for pregnant women. While the market size is projected to be exceeding $8 billion or so, the regulatory development timelines are long for RSV pediatric drug development.

• There is no approved drug for Measles.

• There is no approved drug for MPox.

• The Smallpox approved drugs (under FDA Animal Rule) have significant shortcomings, leaving the US practically unprepared for this bioterrorism scenario despite several billions of dollars in development and acquisitions.

• The approved drugs for Influenza are unlikely to meet the challenge of an H5N1 or highly pathogenic influenza virus epidemic.

NV-387, based on relevant animal model studies, and based on safety and tolerability observed in a Phase I human clinical trial, can fulfill these glaring gaps in pandemic preparedness for current and emerging threats, as well as for potential bioterrorism threats.
Thus, NV-387, as a single drug, is responding to several unmet medical needs in viral infectious diseases at once.

Current Quarter Developments

During the current quarter, we have diligently continued our progress towards initiating a Phase II human safety and effectiveness clinical trial for the evaluation of NV-387 as a treatment of Monkeypox in the Democratic Republic of Congo.

The local regulatory agency, ACOREP, has already approved this Phase II clinical trial, subject to completion of certain requirements.

Africa continues to suffer from the Monkeypox epidemic, which has resulted in the Africa CDC declaring in August 2024 a “Public Health Emergency of Continental Security” (PHECS), a status that continues because this epidemic has continued to expand across national boundaries. This Mpox epidemic is driven by the more morbid and more virulent versions, Clade 1a and 1b, as compared to the 2022 outbreak that was driven by the less virulent Clade 2. The latter has become endemic in the USA and the Western World, but remains limited to sexual transmission primarily in the men-having-sex-with-men (MSM) population. The case fatality rate of Clade 1 has been between 9% to 1.5%, whereas that of Clade 2 is less than 0.3%.

Our objective is to bring the data from the clinical trials external to the USA and utilize it for further regulatory advancement of NV-387 against various indications under the US FDA. NV-387 has certain orphan disease as well as bioterrorism related indications.

Therefore, we first plan to file the appropriate Orphan Drug Designations (ODD) for NV-387 as a treatment for MPOx, Smallpox, and also for Measles. The ODD if approved provides several benefits that would accelerate the NV-387 program towards regulatory licensure. These include frequent FDA meetings and rapid decision-making. Additionally, the economic benefits include certain tax credits for R&D costs, waiver of certain PDUFA fees, and a seven year exclusivity for marketing the drug for the licensed indication.

Company Financials

We reported that, as of September 30, 2025, we had cash and cash equivalent current assets balance of approximately $1.25 Million. In addition, we reported approximately $8.36 Million in total Assets including $6.78 Million of Net Property and Equipment (P&E) assets (after depreciation). The strong P&E assets comprise our cGMP-capable manufacturing and R&D facility in Shelton, CT. The total current liabilities were approximately $1.18 Million.

The net cash utilized during the three months ended September 30, 2025 was approximately $1.59 Million. This included certain non-recurring expenditures including R&D expenditures in preparation for a Phase II clinical trial application. We raised approximately $1.25 Million net of commission and certain expenses in an At-the-Market offering (“ATM”) during the three months ended September 30, 2025.

Additionally, subsequent to the reporting period, we raised approximately $0.68 million in the said ATM offering from October 1 through November 4, 2025.

Further, on November 10, 2025, we raised approximately $5.5 Million in cash after expenses and commissions, in a Registered Direct Offering (“RDO”) and a concurrent private placement offering (both together, the “Offering”) from a single institutional healthcare-focused investor. The overall Offering consisted of (i) 1,970,000 shares of common stock, par value $0.00001 per share (the “Common Stock”), at an offering price of $1.68 per share, and (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 1,601,429 shares of Common Stock, at an offering price of $1.67999 per Pre-Funded Warrant, in the RDO, and in the concurrent private placement with the same investor, the Company has issued and sold Series A warrants to purchase up to 3,571,429 shares of common stock (the “Series A Warrants”) and Series B warrants to purchase up to 3,571,429 shares of common stock (the “Series B Warrants” and, together with the Series A Warrants, the “Warrants”). The Series A Warrants will have an exercise price of $1.75 per share, will be exercisable after 6 months from date of issuance, and will expire 2 years following the issuance date. The Series B Warrants will have an exercise price of $2.00 per share, will be exercisable after 6 months from date of issuance, and will expire 5.5 years following the issuance date.

These financings have added cash amounts of approximately $6.1 million to the Company’s cash balance as of November 12, 2025. Additionally, we continue to have access to an available line of credit of $3 million provided by our founder and President Dr. Anil Diwan. Based on budgeting considerations, we reported that we do not have sufficient funding in hand to continue operations through February 14, 2026, for our planned objectives that include (i) a Phase II clinical trial of NV-387 for MPox infection in Central Africa, (ii) a Phase II clinical trial of NV-387 for Viral Acute and Severe Acute Respiratory Infections (V-ARI and V-SARI), and (iii) Preparation and pre-IND filing for a Phase II clinical trial of NV-387 for RSV indication in the USA.

We note that an additional gross cash financing of $6.25 Million would result into the Company if and when the Series A warrants are exercised. We also note that we continue to have access to the aforementioned ATM Equity Offering. Additionally, we believe we will have access to the equity markets to raise the funds necessary for our current objectives, as we meet various milestones in the ensuing year. We continue to re-prioritize our programs in line with available resources.

Thus we believe that our recent financings have substantially fortified the Company’s fiscal position, and we further believe that we have the ability to continue on our regulatory development plan for NV-387 including the Phase II MPox clinical trial, as well as various planned US FDA engagements for different indications.

We believe our regulatory developments for the orphan diseases and for bioterrorism agents response, provide for a rapid regulatory pathway for US FDA licensure of NV-387, with potential for non-dilutive grant and contracts funding, as well as possible direct US Government acquisition contracts worth hundreds of millions of dollars per year if NV-387 is approved for one of the agents that the US Government stockpiles drugs for. We believe that these early stage revenue opportunities would help us fuel the commercial drug development of NV-387 towards the tens of billions of dollars markets in RSV, Influenza, and other viral infections; as well as to further advance our NV-HHV-1 pan-herpesvirus drug candidate, among others.

About NanoViricides

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections, and even Measles. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

^[1] Yegorov S et al., Effectiveness of influenza vaccination to prevent severe disease: a systematic review and meta- analysis of test-negative design studies, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2025.09.023.

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

Record Net Income of $5.6 Million for the Quarter; Retired All $41 Million of Senior and Seller Debt; Retired All Preferred Shares with Redemption Value of $27 Million; and Increased Shareholder Equity by $22.7 Million

HOUSTON, TEXAS / ACCESS Newswire / November 17, 2025 / EON Resources Inc. (NYSE American:EONR) (“EON” or the “Company”) is an independent upstream energy company with 20,000 leasehold acres in the Permian Basin. The fields have a total of 750 producing and injection wells producing over 1,000 barrels of oil per day. Today, the Company reports revenue and earnings for the third quarter of 2025.

Key third quarter highlights:

On September 9, 2025, $45.5 million of funding closed with the simultaneous settlement of seller obligations and retirement of senior debt: EON and its affiliates successfully closed on total funding of $45.5 million through a combination of volumetric funding instruments (“VMA”) and a farmout of the San Andres formation rights across the leasehold in the Grayburg-Jackson Field (“GJF”) owned and operated by LH Operating, LLC (“LHO”), the Company’s wholly owned subsidiary, for horizontal well development to a subsidiary of Virtus Energy Partners, LLC (“Virtus”).

Sources and Uses of the $45.5 million funding :

• $20.0 million was received from a private family office in consideration for the sale by the LHO of a 15% perpetual overriding royalty interest (“ORRI”) in existing leases and wells in the GJF.

• $20.5 million came from the private family office for the sale by LHO of a 5% perpetual ORRI in production from the San Andres formation in horizontal wells to be drilled under the farmout program by Virtus.

• $5.0 million was received from Virtus in consideration for a farmout of the LHO’s rights in new horizontal wells to be drilled in the San Andres formation in which Virtus will own a 65% operated working interest subject to earning and retention conditions through drilling commitments. LHO will retain a 35% non-operated working interest in such wells.

• EON paid $20.5 million as cash consideration to the seller of the GJF whereby (i) LHO purchased a 10% overriding royalty interest seller had retained in the GJF valued at $13.5 million, (ii) EON retired the $20 million seller note ($15 million principal balance plus accrued interest) for $7.0 million, and (iii) EON issued 1.5 million shares of Class A common stock in exchange for the return to treasury of the preferred units owed by seller with a redemption value of $27 million.

• Retired senior debt of EON of approximately $19.3 million. The payoff of the senior debt eliminated a $700,000 per month amortization payment (principal and interest) and released all oil and gas properties of LHO as collateral for such debt.

“With the completion of the $45 million funding, we have now positioned the Company for expansion and growth ridding ourselves of a weak balance sheet,” said Dante Caravaggio, CEO of EON Resources, Inc. “The Company, through LHO, entered into drilling and production agreements that will spur our growth and support profitability over the coming years.”

The Company entered into a Farmout Agreement (“Farmout”) with Virtus on September 9, 2025: Under the Farmout, Virtus acquired the right to develop LHO’s San Andres formation within the Grayburg Jackson Field under certain conditions and horizontal drilling commitments. Important Farmout provisions follow:

• Virtus paid LHO $5.0 million for the acquisition of a 65% working interest in the leasehold rights in the San Andres formation developed through horizontal drilling. LHO retains a 35% non-operated working interest in the horizontal wells to be drilled by Virtus in the San Andres formation . LHO retains its 100% operated working interest in existing vertical wells and in the remaining formations under lease.

• As many as 90 horizontal wells are expected to be drilled at a cost between $3.5 million to $4.0 million per well. Cumulative capital investment by Virtus and LHO is expected to exceed $300 million over the life of the project.

• The annual horizontal drilling program is expected to range from 10 to 20 new horizontal wells per year with initial production rates of 300 to 500 barrels of oil per day (“BOPD”).

• Over the life of the horizontal drilling program, gross oil production is expected to exceed 20,000 BOPD with 35%, or 7,000 BOPD from the San Andres formation, net to LHO’s 35% working interest.

• The first three wells are anticipated to be completed by mid-year 2026. The costs associated with the drilling and completion of the first three wells are solely the responsibility of Virtus. LHO retains a 35% working interest in these first three wells.

• The Economic Summary Projection of the anticipated development plan prepared by Virtus estimates more than ninety-five million dollars of reserve value based on net present value discounted at ten percent (“NPV-10”) net to LHO’s retained ownership interest.

More information on the funding and farmout can be found in the $45.5 million funding press release, the Farmout press release, and the letter to EON shareholders, which are all located on the Company’s website.

Operational accomplishments during the third quarter:

• Grayburg-Jackson Field had stabilized production and maintained lease operating expenses at reduced levels that have been maintained across 2025.

• By the end of the quarter, over 2 miles of water injector flowlines had been installed on the GJF. Testing and fine-tuning are being performed as needed where the flowlines are expected to be completed in Q4.

• The South Justis Field results started after acquisition by LHO at end of the second quarter, and thus the third quarter reflects the first full quarter of results for SJF.

Financial highlights for the quarter ended September 30, 2025 :

Income statement : Below is a condensed version of the income statement that is included in the 10-Q filing, followed by discussions on certain results and changes from prior quarters.

• Revenues were Consistent: The revenues for the quarter remained consistent with prior quarters as production and prices had only minor fluctuations.

• Lease Operating Expenses (“LOE”) were Consistent: The LOE for the GJF remained consistent at reduced levels across 2025 compared to 2024 LOE levels. The South Justis Field (“SJF”) LOE costs commenced in Q3 of 2025 after acquisition of the SJF adding approximately $475K to the total LOE.

• General and Administrative (“G&A”) Costs had Decline in Recurring Costs: The recurring G&A costs continue to trend downward quarter over the quarter. The Q3-2025 G&A costs included approximately $1.1 million of non-recurring costs attributable to the September 9, 2025 funding.

• Interest Expense was Reduced: As expected, interest expense dropped by approximately $500K for the third quarter compared to the prior quarters due to the retirement of the senior debt and the seller note.

• Gain of $13.4 million on Asset Sale from the Funding: There was a one-time GAAP gain of $13.4 million as a result of the funding and Farmout agreements.

• Gain $1.8 million from Forgiveness of Debt: There was $1.8 million in total gains from the reduction of the senior debt at pay-off and settlement of underwriting fees.

Balance Sheet: Below is a condensed version of the balance sheet that is included in the 10-Q filing, followed by discussions on certain results and changes from prior quarters.

• The GJF Property Value was Reduced due to the ORRIs Conveyance: The GJF recorded property value was reduced by approximately $16 million as an offset to the VMA funding by the ORRIs conveyed.

• Debt was Reduced by Approximately $37 million: With the funding on September 9, 2025, $20 million of senior debt and the $15 million seller note were retired leaving only $5.4 million of convertible notes remaining. The current portion of debt was reduced from $6.1 million in Q2 to $1.0 million at end of Q3.

• Shareholder Equity Increased by a Net $22.7 million: With the retirement of the seller preferred shares, all non-controlling interest was eliminated. The combined impact of the funding, elimination of preferred shares and gains from the funding transactions increased total equity by approximately $22.7 million.

About EON Resources Inc.

EON is an independent upstream energy company focused on maximizing total returns to its shareholders through the development of onshore oil and natural gas properties in a diversified portfolio of long-life producing oil and natural gas properties and other energy holdings. EON’s approach is to build through acquisition and through selective development of its properties. Class A Common Stock of EON trades on the NYSE American Stock Exchange under the symbol of “EONR” and the Company’s public warrants trade under the symbol of “EONRWS”. For more information on the Company, please visit the EON website.

About the Grayburg-Jackson Field Property

Our Grayburg-Jackson Field (“GJF”) is located on the Northwest Shelf of the Permian Basin in Eddy County, New Mexico. The GJF comprises of 13,700 contiguous leasehold acres where the leasehold rights include the Seven Rivers, Queen, Grayburg and San Andres intervals that range from as shallow as 1,500 feet to 4,000 feet in depth. The December 2024 reserve report from our third-party engineer, Haas and Cobb Petroleum Consultants, LLC, estimates proven reserves of approximately 14.0 million barrels of oil and 2.8 billion cubic feet of natural gas. The mapped original-oil-in-place (“OOIP”) is approximately 956 million barrels of oil. The Company has two production programs. The first is the existing waterflood recovery primarily in the Seven Rivers formation via the 550 wells already in place. The second is via a Farmout agreement in the San Andres formation where the recovery will primarily be under the horizontal drilling program whereby the Company expects to participate in drilling up to 90 new wells over the coming years. More information on the property can be located on the Grayburg-Jackson Field page of our website.

About the South Justis Field Property

The South Justis Field (“SJF”) is a carbonate reservoir similar to the rest of the Permian, and is located in Lea County, New Mexico approximately 100 miles from the GJF. The SJF is comprised of 5,360 contiguous acres containing 208 total producing and injection wells with well spacing of 50 acres. The producing formations include the Glorietta, Blinebry, Tubb, Drinkard and Fusselman intervals that range from 5,000 feet to 7,000 feet in depth. The original-oil-in-place (“OOIP”) is approximately 207 million barrels of oil. More information on the property can be located on the South Justis Field page of our website.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to differ materially from what is expected. Words such as “expects,” “believes,” “anticipates,” “intends,” “estimates,” “seeks,” “may,” “might,” “plan,” “possible,” “should” and variations and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Such forward-looking statements relate to future events or future results, based on currently available information and reflect the Company’s management’s current beliefs. A number of factors could cause actual events or results to differ materially from the events and results discussed in the forward-looking statements. Important factors – including the availability of funds, the results of financing efforts and the risks relating to our business – that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents filed from time to time on EDGAR (see www.edgar-online.com) and with the Securities and Exchange Commission (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Investor Relations

Michael J. Porter, President
PORTER, LEVAY & ROSE, INC.
mike@plrinvest.com

SOURCE: EON Resources Inc.

View the original press release on ACCESS Newswire